Synerk Inc

Blue Oak Pharmaceuticals Inc is a pioneering biopharmaceutical company based in Concord, MA, dedicated to revolutionizing the treatment of brain disorders. With a focus on developing first-in-class and best-in-class drugs, their breakthrough approach challenges the traditional target-based methods used by the industry, offering new hope to millions of patients and their families who suffer from mental illness. By utilizing an unbiased approach to systems neuroscience and leveraging their privileged chemistry platform, Blue Oak is able to examine the entire brain circuitry and identify drug-like compounds with high efficiency. Their innovative use of predictive AI design, in collaboration with partners Exscientia and PsychoGenics, optimizes small molecules to normalize the behavioral symptoms of brain disorders. With a robust pipeline of clinical programs targeting bipolar depression, treatment-resistant depression, schizophrenia, and geriatric psychosis, Blue Oak is at the forefront of transforming the CNS drug discovery paradigm.Generated from the website

Stoke Therapeutics, Inc., based in Bedford, MA, is pioneering RNA medicine with its proprietary platform, Targeted Augmentation of Nuclear Gene Output (TANGO), aimed at restoring protein expression in diseases caused by gene mutations. The company's focus is primarily on conditions characterized by haploinsufficiencies, including Dravet syndrome and autosomal dominant optic atrophy (ADOA). Stoke's mission is to develop innovative therapies that address the genetic underpinnings of severe diseases, exemplified by their ongoing clinical studies of zorevunersen (STK-001) for Dravet syndrome. Through their commitment to scientific advancement, they aim to improve the lives of patients living with challenges associated with genetic disorders. Generated from the website

Zenas Biopharma, Inc., located in Waltham, MA, is a dedicated team focused on developing therapies for autoimmune diseases, aiming to address significant unmet patient needs and transform lives. Their investigational drug, Obexelimab, is a bi-functional monoclonal antibody designed to suppress B cell activity, which plays a key role in many autoimmune conditions. The company is committed to understanding patient experiences and introducing transformative therapies that help individuals realize the lives they intended. With a strong emphasis on leadership in the development and commercialization of these therapies, Zenas Biopharma strives to advance its programs across multiple autoimmune diseases. Generated from the website